Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Study shows long-term benefits of pravastatin in unstable angina

Evidence that pravastatin is of long-term benefit when started after hospital admission for unstable angina is provided by the results of a new trial.

A substudy from the LIPID (long-term intervention with pravastatin in ischaemic disease) trial showed that pravastatin improved survival to the end of a six-year follow-up period and that relative benefits appeared to increase with time. In the study, patients were assigned to receive 40mg pravastatin or placebo daily, which was started between three and 36 months after diagnosis of unstable angina or acute myocardial infarction.
Pravastatin was equally effective for both conditions. In 3,260 patients with unstable angina, the risk reduction in all-cause mortality with pravastatin was 26.3 per cent. For 5,754 patients with myocardial infarction, this risk reduction was 20.6 per cent.
The researchers, Professor Andrew Tonkin (National Heart Foundation of Australia) and colleagues, comment that the results show the benefits of pravastatin started some time after diagnosis for unstable
angina.
They comment: “In absolute terms, pravastatin treatment of 1,000 patients with unstable angina would have prevented 33 deaths, 24 non-fatal myocardial infarctions and 26 episodes of myocardial revascularisation”(Lancet 2000;356:1871).

 

Citation: The Pharmaceutical Journal URI: 20003915

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.